{"id":9624,"date":"2025-06-23T10:00:44","date_gmt":"2025-06-23T08:00:44","guid":{"rendered":"https:\/\/www.seventure.fr\/?p=9624"},"modified":"2025-06-24T10:40:12","modified_gmt":"2025-06-24T08:40:12","slug":"enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/","title":{"rendered":"Enterome presents positive Phase 2 interim results in relapsed\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[101,105],"tags":[],"class_list":["post-9624","post","type-post","status-publish","format-standard","hentry","category-life-sciences-en","category-microbiome-nutrition-foodtech-lifestyle"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enterome presents positive Phase 2 interim results in relapsed\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML | Seventure<\/title>\n<meta name=\"description\" content=\"60% (12\/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphoma.EO2463 plus R2 combination treatment resulted in higher-than-expected rates of complete remission so far in this study compared to historical data for R2 alone.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Romane Brunet\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\\\/\"},\"author\":{\"name\":\"Romane Brunet\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#\\\/schema\\\/person\\\/990cba5bd0870778fd29b092bb2bacd5\"},\"headline\":\"Enterome presents positive Phase 2 interim results in relapsed\\\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML\",\"datePublished\":\"2025-06-23T08:00:44+00:00\",\"dateModified\":\"2025-06-24T08:40:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\\\/\"},\"wordCount\":19,\"articleSection\":[\"Life Sciences\",\"Microbiome \\\/ Nutrition \\\/ Foodtech \\\/ Lifestyle\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\\\/\",\"url\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\\\/\",\"name\":\"Enterome presents positive Phase 2 interim results in relapsed\\\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML | Seventure\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#website\"},\"datePublished\":\"2025-06-23T08:00:44+00:00\",\"dateModified\":\"2025-06-24T08:40:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#\\\/schema\\\/person\\\/990cba5bd0870778fd29b092bb2bacd5\"},\"description\":\"60% (12\\\/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphoma.EO2463 plus R2 combination treatment resulted in higher-than-expected rates of complete remission so far in this study compared to historical data for R2 alone.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.seventure.fr\\\/en\\\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enterome presents positive Phase 2 interim results in relapsed\\\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#\\\/schema\\\/person\\\/990cba5bd0870778fd29b092bb2bacd5\",\"name\":\"Romane Brunet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"caption\":\"Romane Brunet\"},\"url\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/author\\\/romane-brunet\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enterome presents positive Phase 2 interim results in relapsed\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML | Seventure","description":"60% (12\/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphoma.EO2463 plus R2 combination treatment resulted in higher-than-expected rates of complete remission so far in this study compared to historical data for R2 alone.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/","twitter_misc":{"Written by":"Romane Brunet"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/#article","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/"},"author":{"name":"Romane Brunet","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5"},"headline":"Enterome presents positive Phase 2 interim results in relapsed\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML","datePublished":"2025-06-23T08:00:44+00:00","dateModified":"2025-06-24T08:40:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/"},"wordCount":19,"articleSection":["Life Sciences","Microbiome \/ Nutrition \/ Foodtech \/ Lifestyle"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/","url":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/","name":"Enterome presents positive Phase 2 interim results in relapsed\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2025-06-23T08:00:44+00:00","dateModified":"2025-06-24T08:40:12+00:00","author":{"@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5"},"description":"60% (12\/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphoma.EO2463 plus R2 combination treatment resulted in higher-than-expected rates of complete remission so far in this study compared to historical data for R2 alone.","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/en\/enterome-presents-positive-phase-2-interim-results-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-after-eo2463-oncomimics-immunotherapy-treatment-at-icml\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Enterome presents positive Phase 2 interim results in relapsed\/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics\u2122 immunotherapy treatment at ICML"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5","name":"Romane Brunet","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","caption":"Romane Brunet"},"url":"https:\/\/www.seventure.fr\/en\/author\/romane-brunet\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=9624"}],"version-history":[{"count":0,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9624\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media?parent=9624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/categories?post=9624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/tags?post=9624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}